Dermavant Sciences Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Dermavant Sciences's estimated annual revenue is currently $8.5M per year.
- Dermavant Sciences received $100.0M in venture funding in August 2018.
- Dermavant Sciences's estimated revenue per employee is $144,492
- Dermavant Sciences has 59 Employees.
- Dermavant Sciences grew their employee count by 5% last year.
- Dermavant Sciences currently has 2 job openings.
|Kenneth Peist||VP, Intellectual Property|
|Ariel Jasie||Chief Business & Strategy Officer|
|Leandro Santos||Director, Topical Drug Delivery & Early DMPK|
|Stephen Andrews||Associate Director, Pharmaceutical Development - Analytical CMC|
|Paul Seaback||SVP, Technical Operations|
|Jen Lustig||Executive Director, Human Resources|
|Alan Colborn||Director, Pharmaceutical Development, Analytical|
|Chad Berryhill||Executive Director of IT|
|Steve Piscitelli||Vice President, Clinical Pharmacology|
|Kara Stancell||VP, Investor Relations & Corporate Communications|
What Is Dermavant Sciences?
A Passion for Science and a Commitment to Dermatology Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. We are dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients lives. The patient is at the heart of everything we do.keywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Sun Devil Athle...||$8.2M||57||12%||N/A|
|Statistics & Da...||$14.1M||97||20%||N/A|
Dermavant Sciences News
Dermavant Sciences, a Phase 3 biotech developing in-licensed therapies for dermatological diseases, officially withdrew its plans for an initial ...
Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment ...
Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update ...
Dermavant Sciences Funding
|2018-08-29||$100.0M||Undisclosed||NovaQuest Capital Management||Article|
Dermavant Sciences Executive Hires
|2018-04-04||David Rubenstein||Chief Scientific Officer||Article|
|2018-09-05||Frank Torti||Executive Chair||Article|
|2019-01-03||Philip Brown||Chief Medical Officer||Article|
|2019-03-28||Cyril Allouche||Chief Financial Officer (Chief Financial Officer)||Article|